Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note

Zacks12-25 06:45

Novo Nordisk (NVO) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494640990?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","is_english":true,"pubTime":"2024-12-25 06:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2494640990","market":"us","top_or_hot":-1,"title":"Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note","media":"Zacks","content":"<div>\n<p>Novo Nordisk (NVO) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time,...</p>\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisk-nvo-stock-drops-224517896.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-25 06:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novo-nordisk-nvo-stock-drops-224517896.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk (NVO) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time,...</p>\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisk-nvo-stock-drops-224517896.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://finance.yahoo.com/news/novo-nordisk-nvo-stock-drops-224517896.html","article_id":"2494640990","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494640990","pubTimestamp":1735080317,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Novo Nordisk  closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 1.35%.The the stock of drugmaker has fallen by 15.16% in the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company is predicted to post an EPS of $0.88, indicating a 23.94% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.67 billion, showing a 22.7% escalation compared to the year-ago quarter.Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favo","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","NVO":"诺和诺德","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4588":"碎股","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"尽管市场上涨，诺和诺德(NVO)股价仍下跌：需要注意的重要事实","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk (NVO) closed the most recent trading day at $87.37, moving -1.51% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.1%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 1.35%.\nThe the stock of drugmaker has fallen by 15.16% in the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 0.22%.\nThe upcoming earnings release of Novo Nordisk will be of great interest to investors. The company is predicted to post an EPS of $0.88, indicating a 23.94% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $11.67 billion, showing a 22.7% escalation compared to the year-ago quarter.\nFor the annual period, the Zacks Consensus Estimates anticipate earnings of $3.23 per share and a revenue of $40.62 billion, signifying shifts of +19.63% and +20.49%, respectively, from the last year.\nInvestors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.\nOur research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.\nThe Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.21% higher. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.\nIn terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 27.46. Its industry sports an average Forward P/E of 13.85, so one might conclude that Novo Nordisk is trading at a premium comparatively.\nWe can also see that NVO currently has a PEG ratio of 1.14. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.46 as of yesterday's close.\nThe Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 140, which puts it in the bottom 45% of all 250+ industries.\nThe Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.\nRemember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494640990"}